Canaccord Genuity Assumes Corcept Therapeutics (CORT) at Buy
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $24.14 -0.74%
Rating Summary:
9 Buy, 6 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 31 | New: 13
Rating Summary:
9 Buy, 6 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 31 | New: 13
Join SI Premium – FREE
Canaccord Genuity analyst Edward Nash assumes coverage on Corcept Therapeutics (NASDAQ: CORT) with a Buy rating and a price target of $34.00.
For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.
Shares of Corcept Therapeutics closed at $23.80 yesterday.
You May Also Be Interested In
- Roth Capital Resumes Clene, Inc. (CLNN) at Buy, PT $10
- Maxim Group Starts Interlink Electronics (LINK) at Buy
- BMO Capital Starts Rexford Industrial Realty (REXR) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
